Business Activities

Research and Development

Research

Mochida's Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.

Development

Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.

Pipeline

As of October 31,2014
Code Name Indications Formulation Stage Remarks
MLD-55 escitalopram Social anxiety disorder Oral Preparation for submission Licensed-in from Lundbeck (Denmark)
MD-0901 mesalazine Ulcerative colitis Oral Phase III Licensed-in from Shire Pharmaceuticals Group
(UK)
MJR-35 dienogest Uterine adenomyosis Oral Phase III Licensed-in from Jenapharm (Bayer Pharma AG)
LBEC0101 etanercept Rheumatoid arthritis Injection Preparation for Phase III Biosimilar (Follow-on biologics)
Licensed-in from LG Life Sciences(Korea)
MTD-39 imiquimod common warts Topical Early Phase II Licensed-in from iNova Pharmaceuticals